GLUCOPHAGE® (metformin hydrochloride) Notification to HCPs and Patients


GLUCOPHAGE® (metformin hydrochloride) was previously commercialized by Bristol-Myers Squibb (BMS) in the U.S., and BMS has decided to discontinue commercialization. Merck KGaA, Darmstadt, Germany licensed to BMS the rights to the product when it was originally approved in the U.S.; today, the rights to GLUCOPHAGE are in the process of transferring to EMD Serono in the U.S.
Due to the company’s strategic focus and resourcing, EMD Serono decided not to commercialize GLUCOPHAGE in the U.S. at this time. Patients currently taking GLUCOPHAGE should speak directly with their healthcare team about the treatment plan that best meets their needs.
As the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada, we are focused exclusively on specialty care conditions including multiple sclerosis, oncology, fertility and HIV-associated wasting. We continue to explore and seek to develop potential new medicines in oncology, immuno-oncology, neurology and immunology.